Viatris Reports Third-Quarter 2026 Financial Results
Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including...
Covered in this story
Call it yourself
No calls on $VTRS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Viatris →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.